Skip to Content

Adrucil (fluorouracil) Disease Interactions

There are 5 disease interactions with Adrucil (fluorouracil):

Major

5- Fu (Includes Adrucil) ↔ Myelosuppression

Severe Potential Hazard, High plausibility

Applies to: Bone Marrow Depression/Low Blood Counts

5- FU can cause severe and fatal myelosuppression. Therapy with 5- FU should be administered cautiously in patients who have had prior high-dose pelvic irradiation or alkylating agents or who have widespread metastatic tumor involvement of the bone marrow. Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding. Close clinical monitoring of hematopoietic function is recommended and therapy should be withheld if platelet counts falls below 100,000/mm3 and/or white blood cell (WBC) counts falls below 3500/mm3 or a rapid fall in WBC is noted.

References

  1. "Product Information. Fluorouracil Injection (fluorouracil)." Roche, Nutley, NJ.
Major

5-Fu (Includes Adrucil) ↔ Dihydropyrimidine Dehydrogenase Deficiency

Severe Potential Hazard, High plausibility

Applies to: Enzymopathy (Unspecified)

Fluorouracil is metabolized to an inactive form by dihydropyrimidine dehydrogenase. Inherited deficiency of this enzyme results in decreased clearance of 5-FU and severe toxicity such as stomatitis, diarrhea, neutropenia, and neurotoxicity. Rechallenge with dosage reduction resulted in recurrence and progression of toxicity. Therapy with fluorouracil should not be administered to patients with dihydropyrimidine deficiency.

References

  1. "Product Information. Fluorouracil Injection (fluorouracil)." Roche, Nutley, NJ.
Major

5-Fu (Includes Adrucil) ↔ Stomatitis

Severe Potential Hazard, Moderate plausibility

Applies to: Inflammatory Bowel Disease, Peptic Ulcer

Fluorouracil (5-FU) induces stomatitis in the gastrointestinal tract. Therapy with 5-FU should be administered with extreme caution in patients with peptic ulcer disease and ulcerative colitis.

References

  1. "Product Information. Fluorouracil Injection (fluorouracil)." Roche, Nutley, NJ.
Moderate

5- Fu (Includes Adrucil) ↔ Bleeding

Moderate Potential Hazard, Moderate plausibility

Applies to: Bleeding

Fluorouracil (5- FU) induces myelosuppression, including thrombocytopenia. Therapy with 5- FU should be administered cautiously in patients with bleeding tendencies. Therapy with 5- FU should be promptly discontinued following bleeding from any sight. Patients should be instructed to immediately report any signs or symptoms suggesting bleeding such as petechiae, purpura, hematuria, or melena. Close clinical monitoring of hematopoietic function is recommended. Therapy with 5- FU should be withheld if platelet counts falls below 100,000/mm3.

References

  1. "Product Information. Fluorouracil Injection (fluorouracil)." Roche, Nutley, NJ.
Moderate

Fluorouracil (Includes Adrucil) ↔ Coronary Artery Disease

Moderate Potential Hazard, Moderate plausibility

Applies to: Cardiovascular Disease

Fluorouracil can cause cardiotoxicity, including angina, myocardial infarction, arrhythmia and heart failure based on post marketing reports. Reported risk factors for cardiotoxicity include administration by continuous infusion rather than intravenous bolus and presence of coronary artery disease. Caution and monitoring is advised in patients with coronary artery disease. Treatment should be discontinued for cardiotoxicity. The risks of treatment resumption after cardiotoxicity has been resolved have not been established.

Adrucil (fluorouracil) drug Interactions

There are 269 drug interactions with Adrucil (fluorouracil)

Adrucil (fluorouracil) alcohol/food Interactions

There is 1 alcohol/food interaction with Adrucil (fluorouracil)

Drug Interaction Classification

The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No information available.

Do not stop taking any medications without consulting your healthcare provider.

Disclaimer: Every effort has been made to ensure that the information provided by Multum is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. Multum's information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill, knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2018 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.

Hide